BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical

Segment
Drug Discovery





 Company News
Boston-Based Intarcia Therapeutics, Inc. Grabs $200 Million To Beef Up Pipeline 4/1/2014 7:24:14 AM    More...
Intarcia Therapeutics, Inc. CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan 1/13/2014 8:41:33 AM    More...
Intarcia Therapeutics, Inc. Appoints Nancy Thornberry To Board Of Directors 12/3/2013 8:05:10 AM    More...
Intarcia Therapeutics, Inc. Appoints Raymond Keane Vice President, General Counsel, and Chief Legal Officer 9/9/2013 8:36:10 AM    More...
Intarcia Therapeutics, Inc. Appoints Gino Santini to Its Board of Directors 7/26/2013 9:39:02 AM    More...
Intarcia Therapeutics, Inc. Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs 7/17/2013 7:19:34 AM    More...
Intarcia Therapeutics, Inc. Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies 6/13/2013 3:06:40 PM    More...
Intarcia Therapeutics, Inc. Enrolls First Patients in "Freedom" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes 3/21/2013 11:24:10 AM    More...
Intarcia Therapeutics, Inc. Appoints Owen Hughes Chief Business Officer and Head of Corporate Development 2/5/2013 7:19:41 AM    More...
Intarcia Therapeutics, Inc. Secures $210 Million Financing to Fund Its Global Phase 3 Program 11/15/2012 9:06:52 AM    More...
12345

//-->